Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Oral Azacitidine (CC-486) Monotherapy in Previously Treated Nasopharyngeal Carcinoma
2014-001745-25Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in nasopharyngeal carcinoma (NPC), sponsored by Celgene Corporation. Primary endpoint: Overall response rate (ORR). Started Nov 2014; status: completed.
02
Drugs
azacitidine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2014-001745-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001745-25.